Eli Lilly has agreed to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on developing oral therapies for patients with inflammatory-mediated diseases.  Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across a broad range of disease states with high unmet need.   These include opportunities across cardiometabolic disorders, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!